The effect of gamma-linolenic acid and eicosapentaenoic acid on urokinase activity. 1994

P J du Toit, and C H van Aswegen, and D J du Plessis
Wolmarans Research Laboratory, Department of Urology, HF Verwoerd Hospital, Pretoria, South Africa.

Urokinase (UK) is an important protease enzyme in carcinogenesis, and is involved in the invasion and metastasis of cancer. Thus, regulation of UK activity is likely to be important in healthy cell metabolism. As it has been reported that a decrease in delta 6-desaturated essential fatty acid (EFA) metabolites occurs in malignant cells and that gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA) exert antimutagenic effects, the effects of GLA and EPA on UK activity have been investigated in this study. Both GLA (n-6) and EPA (n-3) acted as competitive inhibitors of UK with Ki values of 120 and 96 microM respectively. No modification of plasmin activity occurred with either 1.4 x 10(-4) M GLA or EPA. These results could explain why malignant cells with decreased EFA concentrations show increased UK activity. The addition of EFAs to available therapeutic regimens may be worth considering in the treatment of cancer.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator
D015118 Eicosapentaenoic Acid Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. 5,8,11,14,17-Eicosapentaenoic Acid,Icosapent,5,8,11,14,17-Icosapentaenoic Acid,Eicosapentanoic Acid,Timnodonic Acid,omega-3-Eicosapentaenoic Acid,Acid, Eicosapentanoic,omega 3 Eicosapentaenoic Acid
D017965 gamma-Linolenic Acid An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed) Gamolenic Acid,gamma-Linolenic Acid, Ammonium Salt,gamma-Linolenic Acid, Cerium Salt,gamma-Linolenic Acid, Indium Salt,gamma-Linolenic Acid, Lithium Salt,gamma-Linolenic Acid, Potassium Salt,gamma-Linolenic Acid, Sodium Salt,gamma-Linolenic Acid, Zinc Salt,Acid, Gamolenic,Acid, gamma-Linolenic,gamma Linolenic Acid,gamma Linolenic Acid, Ammonium Salt,gamma Linolenic Acid, Cerium Salt,gamma Linolenic Acid, Indium Salt,gamma Linolenic Acid, Lithium Salt,gamma Linolenic Acid, Potassium Salt,gamma Linolenic Acid, Sodium Salt,gamma Linolenic Acid, Zinc Salt

Related Publications

P J du Toit, and C H van Aswegen, and D J du Plessis
October 1998, Aging (Milan, Italy),
P J du Toit, and C H van Aswegen, and D J du Plessis
January 1990, Nutrition (Burbank, Los Angeles County, Calif.),
P J du Toit, and C H van Aswegen, and D J du Plessis
June 1987, Lancet (London, England),
P J du Toit, and C H van Aswegen, and D J du Plessis
September 2002, The Journal of surgical research,
P J du Toit, and C H van Aswegen, and D J du Plessis
January 1980, Lancet (London, England),
P J du Toit, and C H van Aswegen, and D J du Plessis
July 1985, Prostaglandins, leukotrienes, and medicine,
P J du Toit, and C H van Aswegen, and D J du Plessis
December 1998, Clinical nutrition (Edinburgh, Scotland),
P J du Toit, and C H van Aswegen, and D J du Plessis
January 1989, The American journal of physiology,
Copied contents to your clipboard!